Fireside Chat: Nisa Leung, Qiming Venture Partners and James Antonopoulos, ROTH Capital Partners on Cross-Pacific Investment Perspectives
5:00 PM - 6:00 PM (PDT), Tuesday, October 13, 2020
This dynamic session will feature James Antonopoulos of ROTH Capital Partners interviewing Nisa Leung, Managing Partner, Healthcare of Qiming Venture Partners about the current climate for cross-Pacific biotech investment. There will also be live text Q&A with the audience to interact with James and Nisa.
Nisa has been recognized by the Forbes Global 100 VC Midas List in 2019 and 2020, named Top 3 Best Female Venture Capitalist in China by Forbes in 2018 and won Venture Capital Professional of the Year by Asian Venture Capital Journal in 2017.
She currently sits on the board of Gan & Lee Pharmaceuticals (SHSE:603087), Zai Lab (NASDAQ: ZLAB), Venus MedTech (HKSE: 2500), Nurotron, dMed, CanSino Biologics (SHSE: 688185, HKSE: 6185), New Horizon Bio, Berry Oncology, Insilico Medicine among others. Her other investments include Aeonmed Medical, Berry Genomics (SZSE: 000710), CITIC Pharmaceuticals (acquired by Shanghai Pharmaceutical HKSE: 2607), Crown Bioscience (acquired by JSR Life Sciences), Novast Pharmaceuticals, Origene Technologies (acquired by VCAN Bio SHSE: 600645), Richen, Wuxi Leiming, Chain Medical Labs, MEDx, Cure Genetics, SinoCell Tech(SHSE:688520), Apollomics, Sino United, Schrödinger (NASDAQ: SDGR) and Jacobio among others.
She is currently a visiting lecturer at Harvard Law School, a founding vice chair of PhIRDA Investment Committee, Committee member of Hong Kong Innovation and Technology Development and Re-Industrialization and member of Stanford Graduate School of Business Advisory Council. She also serves on the Board of Trustees of the Hotchkiss School and is a board member of the Hong Kong Palace Museum.
Nisa has been recognized by the Forbes Global 100 VC Midas List in 2019 and 2020, named Top 3 Best Female Venture Capitalist in China by Forbes in 2018 and won Venture Capital Professional of the Year by Asian Venture Capital Journal in 2017.
She currently sits on the board of Gan & Lee Pharmaceuticals (SHSE:603087), Zai Lab (NASDAQ: ZLAB), Venus MedTech (HKSE: 2500), Nurotron, dMed, CanSino Biologics (SHSE: 688185, HKSE: 6185), New Horizon Bio, Berry Oncology, Insilico Medicine among others. Her other investments include Aeonmed Medical, Berry Genomics (SZSE: 000710), CITIC Pharmaceuticals (acquired by Shanghai Pharmaceutical HKSE: 2607), Crown Bioscience (acquired by JSR Life Sciences), Novast Pharmaceuticals, Origene Technologies (acquired by VCAN Bio SHSE: 600645), Richen, Wuxi Leiming, Chain Medical Labs, MEDx, Cure Genetics, SinoCell Tech(SHSE:688520), Apollomics, Sino United, Schrödinger (NASDAQ: SDGR) and Jacobio among others.
She is currently a visiting lecturer at Harvard Law School, a founding vice chair of PhIRDA Investment Committee, Committee member of Hong Kong Innovation and Technology Development and Re-Industrialization and member of Stanford Graduate School of Business Advisory Council. She also serves on the Board of Trustees of the Hotchkiss School and is a board member of the Hong Kong Palace Museum.
Moderator
Managing Director, Head of Healthcare Investment Banking
ROTH Capital Partners, LLC
Speakers
Managing Director, Head of Healthcare Investment Banking
ROTH Capital Partners, LLC
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
